This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Biotech Trumps Big Pharma In Our Portfolio

By John Linnemeier

Our three holdings--Geospace Holdings (GEOS), Geely Automobile (GELYY), and 3D Systems (DDD)--began to to perform better in April. I don't think there's much particular justification for most of this, other than the market's manic-depressive attitude toward these companies.

I've decided to buy iShares NASDAQ Biotechnology Index  (IBB), an ETF composed of a large number of biotech companies. Trying to buy individual stocks in this sector is pretty much a crapshoot, and, frankly, there's a good deal of insider information that we'll never have.

On the other hand, the sector, as a whole, appears to be on the upswing for various reasons. In my opinion, Big Pharma simply doesn't have enough new drugs in the pipeline, so the only way to fill it is by buying up smaller companies that have jumped through the respective regulatory hoops for their specific drugs.

The field of genetic engineering, in general, is finally beginning to bear fruit, and I believe may be a revolutionary economic force. I could buy individual stocks, like Seattle Genetics (SGEN), but in this area, at least, I prefer a more diversified approach.

The investments discussed are held in client accounts as of May 1, 2013. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable.

John Linnemeier

John Linnemeier

I'm a writer. The book "How an Average Man Lived an Adventurous Life" is my autobiography. I've spent much of

null

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs